+

WO2010057795A1 - Alkylcyclohexyléthers de dihydrotétrazabenzoazulènes - Google Patents

Alkylcyclohexyléthers de dihydrotétrazabenzoazulènes Download PDF

Info

Publication number
WO2010057795A1
WO2010057795A1 PCT/EP2009/064804 EP2009064804W WO2010057795A1 WO 2010057795 A1 WO2010057795 A1 WO 2010057795A1 EP 2009064804 W EP2009064804 W EP 2009064804W WO 2010057795 A1 WO2010057795 A1 WO 2010057795A1
Authority
WO
WIPO (PCT)
Prior art keywords
trans
chloro
tetraaza
cyclohexyl
benzo
Prior art date
Application number
PCT/EP2009/064804
Other languages
English (en)
Inventor
Patrick Schnider
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2739900A priority Critical patent/CA2739900C/fr
Priority to JP2011535980A priority patent/JP5384659B2/ja
Priority to BRPI0921058A priority patent/BRPI0921058A2/pt
Priority to AU2009317386A priority patent/AU2009317386B2/en
Priority to SG2011035474A priority patent/SG171742A1/en
Priority to PL09747861T priority patent/PL2358714T3/pl
Priority to RU2011121438/04A priority patent/RU2510397C2/ru
Priority to MX2011005119A priority patent/MX2011005119A/es
Priority to ES09747861T priority patent/ES2391374T3/es
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to SI200930344T priority patent/SI2358714T1/sl
Priority to KR1020117011201A priority patent/KR101385433B1/ko
Priority to EP09747861A priority patent/EP2358714B1/fr
Priority to CN200980146033.4A priority patent/CN102216304B/zh
Priority to DK09747861.4T priority patent/DK2358714T3/da
Publication of WO2010057795A1 publication Critical patent/WO2010057795A1/fr
Priority to IL212119A priority patent/IL212119A/en
Priority to ZA2011/02604A priority patent/ZA201102604B/en
Priority to HRP20120816AT priority patent/HRP20120816T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention is concerned with alkylcyclohexylethers of dihydro- tetraazabenzoazulene derivatives, i.e. alkylcyclohexylethers of 5,6-dihydro-4H-2,3,5,10b- tetraaza-benzo[e]azulene derivatives, which act as Via receptor modulators, and in particular as Via receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments.
  • the active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.
  • the present invention is concerned with alkylcyclohexylethers of dihydro- tetraazabenzoazulene derivatives of formula I
  • R 1 , R 2 and R 3 are as described in herewithin.
  • Vasopressin is a 9 amino acid peptide mainly produced by the paraventricular nucleus of the hypothalamus. In the periphery vasopressin acts as a neurohormone and stimulates vasoconstriction, glycogeno lysis and antidiuresis.
  • vasopressin receptors all belonging to the class I G-protein coupled receptors.
  • the Via receptor is expressed in the brain, liver, vascular smooth muscle, lung, uterus and testis
  • the VIb or V3 receptor is expressed in the brain and pituitary gland
  • the V2 receptor is expressed in the kidney where it regulates water reabsorption and mediates the antidiuretic effects of vasopressin (Robben, et al. (2006). Am J Physiol Renal Physiol. 291, F257-70, "Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus"). Compounds with activity at the V2 receptor may therefore cause side-effects on blood homeostasis.
  • the oxytocin receptor is related to the Vasopressin receptor family and mediates the effects of the neurohormone oxytocin in the brain and the periphery. Oxytocin is believed to have central anxiolytic effects (Neumann (2008). J Neuroendocrinol. 20, 858-65, "Brain oxytocin: a key regulator of emotional and social behaviours in both females and males"). Central oxytocin receptor antagonism might therefore lead to anxiogenic effects, which are regarded as undesired side-effects.
  • vasopressin acts as a neuromodulator and is elevated in the amygdala during stress (Ebner, et al. (2002). Eur J Neurosci. 15, 384-8., "Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats"). It is known that stressful life events can trigger major depression and anxiety (Kendler, et al. (2003). Arch Gen Psychiatry.
  • Via receptor is extensively expressed in the brain and particularly in limbic areas like the amygdala, lateral septum and hippocampus which are playing an important role in the regulation of anxiety.
  • Vasopressin or the Via receptor are also implicated in other neuropsychological disorders: genetic studies recently linked sequence polymorphism in the promoter of the human Via receptor to autistic spectrum disorders (Yirmiya, et al. (2006). 11, 488-94, "Association between the arginine vasopressin Ia receptor (AVPRIa) gene and autism in a family-based study: mediation by socialization skills"), intranasal administration of vasopressin was shown to influence aggression in human males (Thompson, et al. (2004). Psychoneuroendocrinology.
  • vasopressin On human facial responses related to social communication
  • vasopressin levels were found to be elevated in schizophrenic patients (Raskind, et al. (1987). Biol Psychiatry. 22, 453-62, "Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients") and patients with obsessive-compulsive disorder (Altemus, et al. (1992). Arch Gen Psychiatry. 49, 9- 20, "Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder").
  • the Via receptor is also mediating the cardiovascular effects of vasopressin in the brain by centrally regulating blood pressure and heart rate in the solitary tract nucleus (Michelini and Morris (1999). Ann N Y Acad Sci. 897, 198-211, "Endogenous vasopressin modulates the cardiovascular responses to exercise”). In the periphery it induces the contraction of vascular smooth muscles and chronic inhibition of the Via receptor improves hemodynamic parameters in myocardial infarcted rats (Van Kerckhoven, et al. (2002). Eur J Pharmacol. 449, 135-41, "Chronic vasopressin V(IA) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats"). Hence, Via antagonists with improved penetration through the blood-brain barrier are expected to be of advantage.
  • vasopressin Via receptor antagonist was shown to be effective in reducing dysmenorrhea in the clinic (Brouard, et al. (2000). Bjog. 107, 614-9, "Effect of SR49059, an orally active Via vasopressin receptor antagonist, in the prevention of dysmenorrhoea"). Via receptor antagonism has also been implicated in the treatment of female sexual dysfunction
  • Via antagonists are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.
  • the preferred indications with regard to the present invention are the treatment of anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.
  • the Via activity may be detected as described in the pharmaceutical test section.
  • alkyl denotes a saturated, i.e. aliphatic, hydrocarbon group including a straight or branched carbon chain. If not further specified, “alkyl” groups denote groups with 1 to 12 carbon atoms, like “C 1-12 -alkyl”. “Ci_ 4 -alkyl” denotes alkyl groups with 1 to 4 carbon atoms and “Ci_ 7 -alkyl” denotes alkyl groups with 1 to 7 carbon atoms.
  • alkyl examples are methyl, ethyl, propyl, isopropyl, n-butyl, iso- butyl, sec-butyl, tert-hvXy ⁇ and the like. Preferred are methyl and i-propyl.
  • alkoxy denotes a group -O-R' wherein R' is alkyl as defined above.
  • Ci_i2-alkoxy denotes alkoxy groups with 1 to 12 carbon atoms
  • Ci_4-alkoxy denotes alkoxy groups with 1 to 4 carbon atoms
  • Ci_7-alkoxy denotes alkoxy groups with 1 to 7 carbon atoms.
  • alkoxy are methoxy, ethoxy, propoxy, te/t-butoxy and the like. Preferred is methoxy.
  • aromatic means the presence of an electron sextet in a ring, according to
  • cyano denotes the group -CN.
  • hydroxy denotes the group -OH.
  • halo or halogen denotes chloro, iodo, fluoro and bromo. Preferred are chloro and fluoro.
  • halo-Ci_ n -alkyl and "Ci_ n -haloalkyl”, alone or in combination with other groups, denote a Ci_ n -alkyl group as defined above , with 1 to n carbon atoms as defined in the specification, wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro.
  • halo-Ci_ n -alkyl examples include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl substituted by one or more Cl, F, Br or I atom(s), in particular one, two or three fluoro or chloro, as well as those groups specifically illustrated by the examples herein below.
  • halo-Ci_ n -alkyl groups are difluoro- or trifluoro -methyl or -ethyl as well as -CF 3 , -CH(CH 3 )CH 2 CF 3 , -CH(CH 3 )CH 2 F.
  • heterocycloalkyl alone or in combination with other groups, as defined herein refers to a monovalent 3 to 7 membered or 4 to 7 membered saturated ring containing one or two heteroatoms selected from N, O or S.
  • heterocycloalkyl alone or in combination with other groups, as defined herein refers to a monovalent 3 to 7 membered ring containing one or two heteroatoms selected from N, O or S.
  • 4-7 membered heterocycloalkyl alone or in combination with other groups, refers to a 4 to 7 membered saturated ring containing one or two heteroatoms selected from N, O or S.
  • heterocycloclakyl moieties are oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, or piperazinyl.
  • Preferred heterocycloalkyl are oxetanyl and tetrahydrofuranyl.
  • Heterocycloalkyl is optionally substituted as described herein.
  • heteroaryl and “5- or 6-membered heteroaryl”, alone or in combination with other groups, refer to a monovalent aromatic 5- or 6-membered monocyclic ring containing one or two ring heteroatoms selected from N, O, or S, the remaining ring atoms being C. 6- Membered heteroaryl are preferred. Examples for heteroaryl moieties include but are not limited to pyridinyl, pyrimidinyl, or pyrazinyl. Preferred is pyridinyl.
  • cycloalkyl and C 3 _ 7 -cycloalkyl refer to a 3 to 7 membered carbon ring, for example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • oxo when referring to substituents on heterocycloalkyl means that an oxygen atom is attached to the heterocycloalkyl ring. Thereby, the “oxo” may either replace two hydrogen atoms on a carbon atom, or it may simply be attached to sulfur, so that the sulfur exists in oxidized form, i.e. bearing one or two oxygens like the group -SO 2 .
  • one or more means from one substituent to the highest possible number of substitution, i.e. replacement of one hydrogen up to replacement of all hydrogens by substituents. Thereby, one, two or three substituents are preferred. Even more preferred are one or two substituents or one substituent.
  • pharmaceutically acceptable salt or “pharmaceutically acceptable acid addition salt” embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
  • hydrochloric acid salt such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
  • the present invention is concerned with alkylcyclohexylethers of dihydro- tetraazabenzoazulene derivatives of formula I
  • R 1 is Ci_i2-alkyl, unsubstituted or substituted with one or more halo, hydroxy, cyano or
  • heterocycloalkyl containing one or two heteroatoms selected from O, N or S, which heterocycloalkyl is unsubstituted or substituted by one or more substituents independently selected from B,
  • R 2 is H
  • Ci_i2-alkyl unsubstituted or substituted with one or more OH, halo, cyano or
  • R a is phenyl or 5- or 6-membered heteroaryl, each unsubstituted or substituted with one or more substituents independently selected from A,
  • alkyl is unsubstituted or substituted with one or more
  • alkyl is unsubstituted or substituted with one or more
  • R 1 and R 11 are each independently H, C 1-12 -alkyl, or form together with the nitrogen to which they are bound a 3- to 7-membered heterocycloalkyl containing one or two heteroatoms selected from N, O or S, which heterocycloalkyl is unsubstituted or substituted by one or more substituents independently selected from B,
  • q 1, 2, 3 or 4
  • r is 2, 3 or 4
  • A is halo, cyano, OH, C 1-7 -alkyl, halo-Ci_7-alkyl, or Ci_7-alkoxy,
  • B is oxo, halo, OH, Ci_7-alkyl or Ci_7-alkoxy,
  • R 3 is Cl or F
  • pharmaceutically acceptable carrier and “pharmaceutically acceptable auxiliary substance” refer to carriers and auxiliary substances such as diluents or excipients that are compatible with the other ingredients of the formulation.
  • composition encompasses a product comprising specified ingredients in pre-determined amounts or proportions, as well as any product that results, directly or indirectly, from combining specified ingredients in specified amounts.
  • a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product that results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • the invention also provides pharmaceutical compositions, methods of using, and methods of preparing the aforementioned compounds.
  • the compounds of formula I may contain asymmetric carbon atoms. Accordingly, the present invention includes all stereoisomeric forms of the compounds of formula I, including each of the individual stereoisomer and mixtures thereof, i.e. their individual optical isomers and mixtures thereof. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric centre will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within this invention. The present invention is meant to comprehend all such isomeric forms of these compounds. The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein.
  • Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric centre of known absolute configuration.
  • racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
  • R 1 is as described above.
  • R 1 is Ci_i2-alkyl, unsubstituted or substituted with one or more halo, hydroxy, cyano or Ci_i2-alkoxy. In certain embodiments, R 1 is Ci_i2-alkyl, unsubstituted or substituted with one or more halo, hydroxy or Ci_i2-alkoxy.
  • R 1 is C3_7 cycloalkyl, unsubstituted or substituted by one or more substituents independently selected from B, wherein B is oxo, halo, OH, Ci_7-alkyl or C 1-7 - alkoxy. In certain embodiments, R 1 is C3_7 cycloalkyl. In certain embodiments, R 1 is 4-7 membered heterocycloalkyl containing one or two heteroatoms selected from O, N or S, which heterocycloalkyl is unsubstituted or substituted by one or more B and B is oxo, halo, OH, Ci_7-alkyl or Ci_7-alkoxy.
  • the 4-7 membered heterocycloalkyl contains one or two heteroatoms selected from O or S, preferably one O, which heterocycloalkyl is unsubstituted or substituted by one or more oxo, halo, OH, Ci_ 7 -alkyl or Ci_ 7 -alkoxy.
  • the heterocycloalkyl is oxetanyl or tetrahydro- pyranyl.
  • R 1 is Ci_i 2 -alkyl, unsubstituted or substituted with one or more halo, hydroxy or Ci_i2-alkoxy,
  • heterocycloalkyl containing one or two heteroatoms selected from Oor S, preferably one O, which heterocycloalkyl is unsubstituted or substituted by one or more oxo, halo, OH, Ci_7-alkyl or Ci_7-alkoxy, preferably unsubstituted.
  • R 1 is -CF 3 , -CH(CH 3 )CH 2 CF 3 , -CH(CH 3 )CH 2 F,
  • R 1 is Ci_i 2 -alkyl or C 3 _7 cycloalkyl.
  • R 1 is i-propyl, cyclobutyl or cyclopentyl.
  • R 1 is unsubstituted Ci_i 2 -alkyl.
  • R 1 is methyl
  • R 1 is ethyl
  • R 1 is isopropyl
  • R 1 is sec-butanyl
  • R 1 is t-butanyl
  • R 1 is Ci_i 2 -alkyl substituted with one or more halo.
  • R 1 is CF 3 .
  • R 1 is CH(CH 3 )CH 2 CF 3 .
  • R 1 is -CH(CH 3 )CH 2 CF 3 . In certain embodiments, R 1 is Ci_i2-alkyl substituted with one or more hydroxy.
  • R 1 is -CH(CH 3 )CH 2 OH.
  • R 1 is Ci_i2-alkyl substituted with one or more Ci_i2-alkoxy.
  • R 1 is -CH(CH 3 )CH 2 OH.
  • R 1 is C 3 _7 cycloalkyl.
  • R 1 is cyclobutyl
  • R 1 is cyclohexyl
  • R 1 is cyclopentyl
  • R 1 is 4-7 membered heterocycloalkyl containing one or two heteroatoms selected from O or S, preferably one O, which heterocycloalkyl is unsubstituted.
  • R 1 is oxetanyl
  • R 1 is tetrahydro-pyranyl.
  • R 2 is as described above.
  • R 2 is H, Ci_i2-alkyl, unsubstituted or substituted with one or more OH, -(CH2) q -R a , wherein R a is phenyl or 5- or 6-membered heteroaryl and q is 1, 2, 3 or 4,
  • alkyl is unsubstituted or substituted with one or more OH
  • R 2 is Ci_i 2 -alkyl.
  • R 2 is 2-hydroxy-ethyl, -C(O)CH 2 OC(O)methyl,
  • R 2 is H. Thereby, forming either the free base or a pharmaceutically acceptable acid addition salt with an inorganic or organic acid such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
  • the free base and a hydrochloric salt are preferred.
  • R 2 is Ci_i2-alkyl, unsubstituted or substituted with one or more OH, halo, cyano or Ci_i2-alkoxy.
  • R 2 is Ci_i2-alkyl, unsubstituted or substituted with one or more OH.
  • R 2 is unsubstituted Ci_i2-alkyl.
  • R 2 is methyl
  • R 2 is isopropyl
  • R 2 is Ci_i2-alkyl, substituted with one or more OH.
  • R 2 is 2-hydroxy-ethyl.
  • R 2 is -(CH2) q -R a , wherein R a is phenyl or 5- or 6-membered heteroaryl, each unsubstituted or substituted with one or more substituents independently selected from A, and A is halo, cyano, OH, Ci_7-alkyl, halo-Ci_7-alkyl, or Ci_7-alkoxy; and q is 1, 2, 3 or 4, preferably 1.
  • R 2 is -(CH2) q -R a , wherein R a is phenyl or 5- or 6- membered heteroaryl and q is 1, 2, 3 or 4, preferably 1.
  • R 2 is -CH 2 - pyridinyl or benzyl, preferably R 2 is -CH 2 -pyridin-2-yl.
  • R 2 is -C(O)-C i_i 2 -alkyl, wherein alkyl is unsubstituted or substituted with one or more OH, halo, cyano or Ci_i2-alkoxy. In certain embodiments, R 2 is - C(O)-C i_i 2 -alkyl, wherein alkyl is unsubstituted or substituted with one or more OH.
  • R 2 is -C(O)hydroxymethyl.
  • R 2 is -C(O)methyl.
  • R 2 is -C(O)(CH 2 ) q OC(O)-Ci_i 2 -alkyl, wherein q is 1, 2, 3 or 4, preferably 1.
  • R 2 is -C(O)CH 2 OC(O)methyl
  • R 2 is -C(0)0-Ci_i 2 -alkyl, wherein alkyl is unsubstituted or substituted with one or more OH, halo, cyano or Ci_i2-alkoxy. In certain embodiments, R 2 is -C(0)0-Ci_i 2 -alkyl.
  • R 2 is -C(O)O-t-butyl.
  • R 2 is -S(O) 2 -Ci_i 2 -alkyl.
  • R 2 is -S(O) 2 NR 1 R 11 , wherein R 1 and R 11 are each independently H, Ci_i 2 -alkyl, or form together with the nitrogen to which they are bound a 3- to 7-membered heterocycloalkyl containing one or two heteroatoms selected from N, O or S, which heterocycloalkyl is unsubstituted or substituted by one or more substituents independently selected from B, and B is oxo, halo, OH, Ci_7-alkyl or Ci_7-alkoxy.
  • R 2 is -S(O) 2 NR 1 R 11 , wherein R 1 and R 11 are each independently H or Ci_i 2 -alkyl, preferably Ci_i 2 -alkyl.
  • R 2 is -S(0) 2 methyl.
  • R 2 is H
  • Ci_i2-alkyl unsubstituted or substituted with one or more OH
  • R a is phenyl or 5- or 6-membered heteroaryl and q is 1, 2, 3 or 4, preferably 1,
  • alkyl is unsubstituted or substituted with one or more
  • R 1 and R 11 are each independently H or C 1-12 -alkyl, preferably Ci_i 2 -alkyl.
  • R 3 is Cl or F.
  • R 3 is Cl.
  • R 3 is F.
  • R 1 is Ci_i2-alkyl, unsubstituted or substituted with one or more halo, hydroxy or C 1-12 - alkoxy, C 3 - 7 -cycloalkyl,
  • heterocycloalkyl containing one or two heteroatoms selected from O or S, preferably one O, which heterocycloalkyl is unsubstituted or substituted by one or more oxo, halo, OH, Ci_7-alkyl or Ci_7-alkoxy, preferably unsubstituted,
  • R 2 is H
  • Ci_i2-alkyl unsubstituted or substituted with one or more OH
  • R a is phenyl or 5- or 6-membered heteroaryl and q is 1, 2, 3 or 4, preferably 1,
  • alkyl is unsubstituted or substituted with one or more
  • R 1 and R 11 are each independently H or Ci_i 2 -alkyl, preferably C 1-12 -alkyl,
  • R is Cl or F
  • the compound of formula I is provided as a subset of formula I '
  • HG is selected from
  • HG-1 HG-2 HG-3 HG-4 and R 1 , R 2 and R 3 are as described above, including all combinations thereof.
  • trans-8-chloro-l-(4-isopropoxy-cyclohexyl)-5-methyl-5,6- dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene trans-8-chloro-l-(4-cyclobutoxy-cyclohexyl)-5- methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene
  • trans-8-chloro-l-(4- cyclopentyloxy-cyclohexyl)-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene trans-8-chloro-l-(4-isopropoxy-cyclohexyl)-5-methyl-5,6- dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene
  • a certain embodiment of the invention is a compound as described in any of the embodiments obtainable by a process according as described herewithin.
  • a certain embodiment of the invention is a compound as described in any of the embodiments, whenever obtained by a process according as described herewithin.
  • a certain embodiment of the invention is a compound as described in any of the embodiments for the use as therapeutically active substance.
  • a certain embodiment of the invention is a compound as described in any of the embodiments for a use in the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.
  • a certain embodiment of the invention is a pharmaceutical composition comprising a compound as described in any of the embodiments.
  • a certain embodiment of the invention is a pharmaceutical composition comprising a compound as described in any of the embodiments, wherein it is useful for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.
  • a certain embodiment of the invention is the use of a compound as described in any of the embodiments for the preparation of a medicament.
  • a certain embodiment of the invention is the use of a compound as described in any of the embodiments for the preparation of a medicament, wherein the medicament is useful for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.
  • a certain embodiment of the invention is the use of a compound as described in any of the embodiments for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.
  • a certain embodiment of the invention is a method for the therapeutic and/or prophylactic treatment of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior, which method comprises administering a compound as defined in any if the embodiments to a human being or animal.
  • the compounds of formula (I) of the invention can be manufactured according to a process comprising the step of reacting a compound of formula (II)
  • Scheme 2 Compounds of formula (I) with R different from H can be prepared from compounds of formula (I-b) (compounds of formula (I) wherein R 2 is H) according to methods known in the art, e.g. by treating a compound of formula (I-b) with an inorganic base such as a carbonate salt or an organic base such as a tertiary amine and an electrophilic reactant R 2 -LG (wherein LG is a leaving group, e.g. halogen or sulfonyl) which is either commercially available or easily prepared according to methods and starting materials well known in the art.
  • an inorganic base such as a carbonate salt or an organic base such as a tertiary amine
  • R 2 -LG wherein LG is a leaving group, e.g. halogen or sulfonyl
  • compounds of formula (I) can be obtained via reductive alkylation by consecutively treating a compound of formula (I-b) with a ketone or aldehyde and a suitable reducing agent, e.g. a borohydride derivative such as sodium borohydride, sodium cyanoborohydride or sodium triacetoxyborohydride.
  • a suitable reducing agent e.g. a borohydride derivative such as sodium borohydride, sodium cyanoborohydride or sodium triacetoxyborohydride.
  • Compounds of formula (I-b) can be obtained by cleavage of the substituent R 2 of compound of formula I using methods known in the art.
  • Thio lactam derivatives of formula (III-l) (compounds of formula (III) in which R 2 is tert- butoxycarbonyl) can be obtained as follows: Transformation of a 2-nitrobenzyl alcohol of formula (a) to a benylic chloride of formula (b) can be effected by a chlorinating reagent such as thionyl chloride in the presence of an organic tertiary amine base.
  • a thiolactam derivative of formula (III-l) is obtained by treatment of a compound of formula (f) with Lawesson's reagent (2,4-bis-(4-methoxyphenyl)-l,3,2,4-dithiadiphosphetane-2,4-disulfide) or phosphorous pentasulfide at elevated temperature.
  • 4-Alkoxy-cyclohexanecarboxylic acid ester derivatives of formula (VII) can be obtained by reductive etherification as follows: 4-Hydroxy-cyclohexanecarboxylic acid ethyl ester (IV) is converted to 4-trimethylsilanyloxy-cyclohexanecarboxylic acid ethyl ester (V) by O-silylation methods known in the art, e.g. by treatment with a silylating agent such as trimethylsilyl chloride or trimethylsilyl triflate in the presence of a base such as imidazole or 2,6-lutidine in a suitable solvent such as N,N-dimethylformamide or dichloromethane.
  • a silylating agent such as trimethylsilyl chloride or trimethylsilyl triflate
  • a base such as imidazole or 2,6-lutidine
  • a suitable solvent such as N,N-dimethylformamide or dichlor
  • 4-alkoxy-cyclohexanecarboxylic acid ester derivatives of formula (VII) can be obtained by reductive etherif ⁇ cation as follows: Consecutive treatment of an alkoxy- trimethyl-silane of formula (IX) and 4-cyclohexanonecarboxylic acid ethyl ester (X) with trimethylsilyl triflate in dichloromethane and a reducing agent such as triethylsilane gives A- alkoxy-cyclohexanecarboxylic acid ester derivatives of formula (VII).
  • Consecutive treatment of an alkoxy- trimethyl-silane of formula (IX) and 4-cyclohexanonecarboxylic acid ethyl ester (X) with trimethylsilyl triflate in dichloromethane and a reducing agent such as triethylsilane gives A- alkoxy-cyclohexanecarboxylic acid ester derivatives of formula (VII).
  • (VII) are usually obtained as a mixture of cis- and trans-isomers, which can in some cases be separated chromato graphically to give the pure trans-4-alkoxy-cyclohexanecarboxylic acid ester of formula (VII-a) and cis-4-alkoxy-cyclohexanecarboxylic acid ester of formula (VII-b).
  • Alkoxy-trimethyl-silane derivatives of formula (IX) are either commercially available or are prepared using O-silylation methods known in the art, e.g.
  • alkoxy-trimethyl-silane derivatives of formula (IX) can be prepared in situ without isolation prior to the reductive etherif ⁇ cation step with 4-cyclohexanonecarboxylic acid ethyl ester (X) by treating an alcohol of general formula
  • An oxetan-3-yloxy derivatives of formula (VII-4) can be obtained by treatment of the compound of formula (VII-3) with potassium tert-butoxide in toluene at reflux.
  • the compound of formula (VII-3) is formed by monotosylation of the dihydroxy derivative of formula (VII-2), which is prepared by hydro geno lytic double-O-debenzylation of the compound of formula (VII- 1).
  • the compound of formula (VII-I) can be obtained from l,3-dibenzyloxy-2-propanol according to the reductive etherif ⁇ cation procedure described in general scheme E.
  • 4-Trifluoromethox-cyclohexanecarboxcylic acid ethyl ester (VII-5) can be prepared by treatment of intermediate (XI) with N-bromosuccinimide and HF-pyridine in dichloromethane.
  • Compound (XI) is obtained by O-deprotonation of 4-hydroxy-cyclohexanecarboxylic acid ethyl ester with sodium hydride followed by sequential addition of carbon disulfide and methyl iodide.
  • cis/trans-4-tert-Butoxy-cyclohexanecarboxylic acid ethyl ester (VII-6) can be prepared by treating cis/trans-4-hydroxy-cyclohexanecarboxylic acid ethyl ester (IV) with di-tert-butyl dicarbonate in the presence of magnesium chloride.
  • the pure trans isomer (VII-6-a) and the pure cis isomer (VII-6-b) can be obtained by chromatographic separation.
  • a 4-aryloxy-cyclohexanecarboxylic acid ester of formula (VII) can be converted to a hydrazide derivative of formula (II) by heating with hydrazine hydrate.
  • an ester derivative of formula (VII) can be hydrolyzed to a carboxylic acid derivative of formula (XII) using a biphasic mixture of aqueous sodium or potassium hydroxide solution and an etheral solvent such as dioxan.
  • a hydrazide derivative of formula (II) can be obtained by activating an acid intermediate of formula (XII), e.g.
  • the corresponding pharmaceutically acceptable salts with acids can be obtained by standard methods known to the person skilled in the art, e.g. by dissolving the compound of formula I in a suitable solvent such as e.g. dioxan or THF and adding an appropriate amount of the corresponding acid.
  • a suitable solvent such as e.g. dioxan or THF
  • the products can usually be isolated by filtration or by chromatography.
  • the conversion of a compound of formula I into a pharmaceutically acceptable salt with a base can be carried out by treatment of such a compound with such a base.
  • One possible method to form such a salt is e.g. by addition of 1/n equivalents of a basic salt such as e.g.
  • a suitable solvent e.g. ethanol, ethanol-water mixture, tetrahydrofuran- water mixture
  • the compounds of formula I as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth herewithin. Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in analogy thereto. It will be appreciated that the compounds of general formula I in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • the compounds of the present invention exhibit Via activity. They are selective inhibitors of the Via receptor and are therefore likely to have a low potential to cause unwanted off-target related side-effects.
  • the Via activity may be detected as described below.
  • the human Via receptor was cloned by RT-PCR from total human liver RNA.
  • the coding sequence was subcloned in an expression vector after sequencing to confirm the identity of the amplified sequence.
  • Cell membranes were prepared from HEK293 cells transiently transfected with the expression vector and grown in 20 liter fermenters with the following protocol.
  • the pellet is resuspended in 12.5 ml Lysis buffer+12.5ml Sucrose 20% and homogenized using a Polytron for 1-2 min.
  • the protein concentration is determined by the Bradford method and aliquots are stored at -80 0 C until use.
  • 60mg Yttrium silicate SPA beads (Amersham) are mixed with an aliquot of membrane in binding buffer (50 mM Tris, 12OmM sodium chloride, 5 mM potassium chloride, 2 mM Calcium dichloride, 10 mM magnesium dichloride) for 15 minutes with mixing.
  • the compounds of formula I as well as their pharmaceutically usable acid addition salts can be used as medicaments, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
  • the compounds of formula I and their pharmaceutically usable acid addition salts can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragees and hard gelatine capsules.
  • Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semisolid and liquid polyols etc.
  • Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.
  • Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
  • Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi- liquid or liquid polyols etc..
  • the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • a daily dosage of about 10 to 1000 mg per person of a compound of general formula I should be appropriate, although the above upper limit can also be exceeded when necessary.
  • compositions according to the invention are, but are not limited to:
  • the compound of formula I, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine.
  • the mixture is returned to the mixer, the talc (and magnesium stearate) is added thereto and mixed thoroughly.
  • the mixture is filled by machine into suitable capsules, e.g. hard gelatine capsules.
  • the compound of formula I is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
  • the filled soft gelatin capsules are treated according to the usual procedures.
  • the suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45°C. Thereupon, the finely powdered compound of formula I is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size, left to cool, the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.
  • the compound of formula I is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
  • the pH is adjusted to 5.0 by acetic acid.
  • the volume is adjusted to 1.0 ml by addition of the residual amount of water.
  • the solution is filtered, filled into vials using an appropriate overage and sterilized.
  • the compound of formula I is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water.
  • the granulate is mixed with magnesiumstearate and the flavoring additives and filled into sachets.
  • An alkoxy-trimethyl-silane intermediate of formula (IX) is formed in situ by adding trimethylsilyl trifluoromethanesulfonate (1 eq) to a solution of an alcohol derivative of formula (VIII) (1 eq) and 2,6-lutidine (1 eq) in dichloromethane (0.1 M) at -78 0 C. After 1 h 4- cyclohexanonecarboxylic acid ethyl ester (X) (0.85 eq) and trimethylsilyl trifluoromethanesulfonate (0.1 eq) are added consecutively. The reaction mixture is stirred for 1 h.
  • 4-Alkoxy-cyclohexanecarboxylic acid ester 4 cis-4-Isopropoxy-cyclohexanecarboxylic acid ethyl ester trans-4-Isopropoxy-cyclohexanecarboxylic acid ethyl ester and cis-4-isopropoxy- cyclohexanecarboxylic acid ethyl ester were obtained from acetone according to general procedure I after separation by flash-column chromatography.
  • trans-4-Isopropoxy-cyclohexanecarboxylic acid ethyl ester was obtained as colorless oil in 23% yield.
  • 4-Alkoxy-cyclohexanecarboxylic acid ester 11 trans-4-Cyclohexyloxy-cyclohexanecarboxylic acid ethyl ester and 4-Alkoxy-cyclohexanecarboxylic acid ester 12 cis-4-Cyclohexyloxy-cyclohexanecarboxylic acid ethyl ester trans-4-Cyclopentoxy-cyclohexanecarboxylic acid ethyl ester and cis-4-cyclopentoxy- cyclohexanecarboxylic acid ethyl ester were obtained from cyclohexanone according to general procedure I after separation by flash-column chromatography.
  • the aqueous layer was extracted with one portion of dichloromethane.
  • the combined organic layers were washed with two 50 ml portions of 2 M aqueous sodium hydroxide solution.
  • the combined aqueous layers were acidified to pH 1 by addition of concentrated hydrochloric acid solution (100 ml).
  • the aqueous layer was extracted with two 150-ml portions of dichloromethane.
  • the combined organic layers from the acidic extraction were dried over anhydrous sodium sulfate and dried in vacuo to give the title compound (0.358 g, 93%) as yellow solid.
  • a solution of an N-BOC derivative of general formula (I-a) (1 eq) in 1.25 M methanolic or 1.5 M ethanolic hydrogen chloride solution (10 - 20 eq HCl) is heated at 50 0 C for 15-60 min. After cooling to room temperature the reaction mixture is concentrated in vacuo to give a secondary amine derivative of general formula (I-b) as hydrochloride salt.
  • the free base can be obtained by partitioning the hydrochloride salt between 1 M aqueous sodium hydroxide solution and an organic solvent, e.g. ethyl acetate or dichloromethane. The layers are separated and the aqueous layer is extracted with two portions of the organic solvent. The combined organic layers are dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give the free base of a compound of formula (I-b).
  • a mixture of a compound of formula (I-b) as free base or as hydrochloride salt (1 eq, 0.1-0.2 M), triethylamine (1 eq when the hydrochloride salt of a compound of formula (I-b) is used) and an aldehyde or ketone (8 eq) in methanol is heated at reflux for 2-6 h. After cooling to 0 0 C sodium cyanoboro hydride (2-3 eq) is added. The reaction mixture is stirred for 3-16 h at room temperature and quenched with 1 M aqueous sodium hydroxide solution. The aqueous layer is extracted with ethyl acetate. The combined organic layers are dried over anhydrous sodium sulfate and concentrated in vacuo. Flash chromatography gives an N-alkyl derivative of formula (I).
  • Example 1 cis-8-Chloro-l-(4-methoxy-cyclohexyl)-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza- benzo[e]azulene a) cis/trans-8-Chloro-l-(4-methoxy-cyclohexyl)-4H,6H-2,3,5,10b-tetraaza-benzo[e]azulene-5- carboxylic acid tert-butyl ester (1 :1) Hydrazide: cis/trans-4-Methoxy-cyclohexanecarboxylic acid hydrazide (1 :1)
  • Example 20 trans-8-Fluoro-l-(4-isopropoxy-cyclohexyl)-5,6-dihydro-4H-2,3,5,10b-tetraaza- benzo[e]azulene hydrochloride
  • the title compound was obtained as white solid in quantitative yield from trans-8-fluoro-l-(4- isopropoxy-cyclohexyl)-4H,6H-2,3,5,10b-tetraaza-benzo[e]azulene-5-carboxylic acid tert-butyl ester using general procedure V.
  • Example 24 cis-8-Chloro-l-(4-isopropoxy-cyclohexyl)-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza- benzo[e]azulene
  • the title compound was obtained as white solid in 90% yield from cis-8-chloro-l-(4-isopropoxy- cyclohexyl)-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene hydrochloride and paraformaldehyde using general procedure VI.
  • (+)-trans-l-(4-sec-Butoxy-cyclohexyl)-8-chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza- benzo[e]azulene and (-)-trans-l-(4-sec-butoxy-cyclohexyl)-8-chloro-5-methyl-5,6-dihydro-4H- 2,3,5, 10b-tetraaza-benzo[e]azulene were obtained from (RS)-trans-l-(4-sec-butoxy-cyclohexyl)- 8-chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene by chiral HPLC separation on a Chiralpak AD column with n-heptane/ethanol (4:1) as eluent.
  • (+)-trans-l-(4-sec-Butoxy-cyclohexyl)-8-chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza- benzo[e]azulene (0.068 g, 36%) was obtained as white solid.
  • Example 38 trans-8-Chloro-l-(4-cyclopentyloxy-cyclohexyl)-5-methyl-5,6-dihydro-4H-2,3,5,10b- tetraaza-benzo [e] azulene
  • the title compound was obtained as white solid in 56% yield from trans-8-chloro-l-(4- cyclopentyloxy-cyclohexyl)-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene hydrochloride and paraformaldehyde using general procedure VI.
  • Example 40 trans-8-Chloro-l-(4-cyclohexyloxy-cyclohexyl)-5,6-dihydro-4H-2,3,5,10b-tetraaza- benzoazulene hydrochloride
  • the title compound was obtained as white solid in 97% yield from trans-8-chloro-l-(4- cyclohexyloxy-cyclohexyl)-4H,6H-2,3,5,10b-tetraaza-benzoazulene-5-carboxylic acid tert-butyl ester using general procedure V.
  • Thiolactam 7-Chloro-2-thioxo-l,2,3,5-tetrahydro-benzo[e][l,4]diazepine-4-carboxylic acid tert- butyl ester.
  • Example 43 cis-8-Chloro-l-(4-cyclohexyloxy-cyclohexyl)-5,6-dihydro-4H-2,3,5,10b-tetraaza- benzoazulene hydrochloride
  • the title compound was obtained as white solid in quantitative yield from cis-8-chloro-l-(4- cyclohexyloxy-cyclohexyl)-4H,6H-2,3,5,10b-tetraaza-benzoazulene-5-carboxylic acid tert-butyl ester using general procedure V.
  • Example 58 trans-8-Chloro-5-methyl-l-[4-(oxetan-3-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b- tetraaza-benzo [e] azulene a) (RS)-trans-3-Chloro-2-[4-(8-chloro-5.6-dihvdro-4H-2.3.5.10b-tetraaza-benzo[elazulen-l-yl)- cyclohexyloxy]-propan- 1 -ol hydrochloride
  • Example 60 cis-8-Chloro-l-[4-(tetrahydro-pyran-4-yloxy)-cyclohexyl]-4H,6H-2,3,5,10b-tetraaza- benzoazulene-5-carboxylic acid tert-butyl ester trans-8-Chloro-l-[4-(tetrahydro-pyran-4-yloxy)-cyclohexyl]-4H,6H-2, 3,5,10b-tetraaza- benzoazulene-5-carboxylic acid tert-butyl ester and cis-8-chloro-l-[4-(tetrahydro-pyran-4- yloxy)-cyclohexyl]-4H,6H-2,3,5,10b-tetraaza-benzoazulene-5-carboxylic acid tert-butyl ester were obtained according to general procedure IV after separation by flash-column chromatography.
  • Hydrazide cis/trans-4-(Tetrahydro-pyran-4-yloxy)-cyclohexanecarboxylic acid hydrazide(l :2)
  • Thiolactam 7-Chloro-2-thioxo-l,2,3,5-tetrahydro-benzo[e][l,4]diazepine-4-carboxylic acid tert- butyl ester trans-8-Chloro-l-[4-(tetrahydro-pyran-4-yloxy)-cyclohexyl]-4H,6H-2, 3,5,1
  • Ob-tetraaza- benzoazulene-5-carboxylic acid tert-butyl ester was obtained as white foam in 26% yield.
  • Example 61 trans-8-Chloro-l-[4-(tetrahydro-pyran-4-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b- tetraaza-benzoazulene hydrochloride
  • the title compound was obtained as white solid in quantitative yield from trans-8-chloro-l-[4- (tetrahydro-pyran-4-yloxy)-cyclohexyl]-4H,6H-2,3,5,10b-tetraaza-benzoazulene-5-carboxylic acid tert-butyl ester using general procedure V.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Luminescent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des dérivés de type alkylcyclohexyléther de dihydrotétrazabenzoazulène, plus précisément des dérivés de type alkylcyclohexyléther de 5,6-dihydro-4H-2,3,5,10b-tétraza-benzo[e]azulène de formule (I) où R1, R2 et R3 sont tels que décrits dans la présente invention. Les composés selon l'invention agissent en tant que modulateurs des récepteurs VIa, et en particulier en tant qu'antagoniste des récepteurs VIa. La présente invention concerne également leur fabrication, les compositions pharmaceutiques les incluant et leur emploi en tant que médicament. Les principes actifs selon l'invention peuvent être employés en tant que produits thérapeutiques à action périphérique ou centrale dans les états de dysménorrhée, de dysfonctionnement sexuel chez l'homme ou la femme, d'hypertension, d'insuffisance cardiaque chronique, de sécrétion inadaptée de vasopressine, de cirrhose du foie, de syndrome néphrotique, d'anxiété, de troubles dépressifs, de troubles obsessionnels compulsifs, de troubles du spectre autistique, de schizophrénie et de comportement agressif.
PCT/EP2009/064804 2008-11-18 2009-11-09 Alkylcyclohexyléthers de dihydrotétrazabenzoazulènes WO2010057795A1 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
ES09747861T ES2391374T3 (es) 2008-11-18 2009-11-09 Alquilciclohexiléteres de dihidrotetraazabenzoazulenos
BRPI0921058A BRPI0921058A2 (pt) 2008-11-18 2009-11-09 éteres alquilciclo-hexílicos de di-hidrotetra-azabenzoazulenos
SI200930344T SI2358714T1 (sl) 2008-11-18 2009-11-09 Alkilcikloheksiletri dihidrotetraazabenzoazulenov
SG2011035474A SG171742A1 (en) 2008-11-18 2009-11-09 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL09747861T PL2358714T3 (pl) 2008-11-18 2009-11-09 Etery alkilocykloheksylowe dihydrotetraazabenzoazulenu
RU2011121438/04A RU2510397C2 (ru) 2008-11-18 2009-11-09 Алкилциклогексиловые эфиры дигидротетраазабензоазуленов
MX2011005119A MX2011005119A (es) 2008-11-18 2009-11-09 Alquilciclohexileteres de dihidrotetraazabenzoazulenos.
CA2739900A CA2739900C (fr) 2008-11-18 2009-11-09 Alkylcyclohexylethers de dihydrotetrazabenzoazulenes
AU2009317386A AU2009317386B2 (en) 2008-11-18 2009-11-09 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
JP2011535980A JP5384659B2 (ja) 2008-11-18 2009-11-09 ジヒドロテトラアザベンゾアズレンのアルキルシクロヘキシルエーテル
KR1020117011201A KR101385433B1 (ko) 2008-11-18 2009-11-09 다이하이드로테트라아자벤조아줄렌의 알킬사이클로헥실에터
EP09747861A EP2358714B1 (fr) 2008-11-18 2009-11-09 Alkylcyclohexyléthers de dihydrotétrazabenzoazulènes
CN200980146033.4A CN102216304B (zh) 2008-11-18 2009-11-09 二氢四氮杂苯并薁的烷基环己基醚
DK09747861.4T DK2358714T3 (da) 2008-11-18 2009-11-09 Alkylcyclohexylethere af dihydrotetraazabenzoazulener
IL212119A IL212119A (en) 2008-11-18 2011-04-04 Alkylcyclohexyl sites of dihydrotutrazanebenzo [e] azoles, processes for their preparation, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases
ZA2011/02604A ZA201102604B (en) 2008-11-18 2011-04-07 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
HRP20120816AT HRP20120816T1 (hr) 2008-11-18 2012-10-11 Alkilcikloheksil eteri od dihidrotetraazabenzoazulena

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08169348.3 2008-11-18
EP08169348 2008-11-18

Publications (1)

Publication Number Publication Date
WO2010057795A1 true WO2010057795A1 (fr) 2010-05-27

Family

ID=41398220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/064804 WO2010057795A1 (fr) 2008-11-18 2009-11-09 Alkylcyclohexyléthers de dihydrotétrazabenzoazulènes

Country Status (25)

Country Link
US (1) US8642590B2 (fr)
EP (1) EP2358714B1 (fr)
JP (1) JP5384659B2 (fr)
KR (1) KR101385433B1 (fr)
CN (1) CN102216304B (fr)
AR (1) AR074354A1 (fr)
AU (1) AU2009317386B2 (fr)
BR (1) BRPI0921058A2 (fr)
CA (1) CA2739900C (fr)
CL (1) CL2011001129A1 (fr)
CY (1) CY1113692T1 (fr)
DK (1) DK2358714T3 (fr)
ES (1) ES2391374T3 (fr)
HR (1) HRP20120816T1 (fr)
IL (1) IL212119A (fr)
MX (1) MX2011005119A (fr)
PE (1) PE20110590A1 (fr)
PL (1) PL2358714T3 (fr)
PT (1) PT2358714E (fr)
RU (1) RU2510397C2 (fr)
SG (1) SG171742A1 (fr)
SI (1) SI2358714T1 (fr)
TW (1) TWI389911B (fr)
WO (1) WO2010057795A1 (fr)
ZA (1) ZA201102604B (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011120877A1 (fr) * 2010-03-31 2011-10-06 F. Hoffmann-La Roche Ag Aryl-cyclohexyl-tétraazabenzo[e]azulènes
WO2011128265A1 (fr) * 2010-04-13 2011-10-20 F. Hoffmann-La Roche Ag Aryl-/hétéroaryl-cyclohexényl-tétraazabenzo[e]azulènes en tant qu'antagonistes de vasopressine
US8227458B2 (en) 2008-11-28 2012-07-24 Hoffmann-La Roche Inc. Arylcyclohexylethers of dihydrotetraazabenzoazulenes
WO2013045373A1 (fr) * 2011-09-26 2013-04-04 F. Hoffmann-La Roche Ag Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulènes en tant qu'antagonistes de v1a
US8481528B2 (en) 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
US8642590B2 (en) 2008-11-18 2014-02-04 Hoffmann-La Roche Inc. Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
US8664216B2 (en) 2008-11-13 2014-03-04 Hoffmann-La Roche Inc. Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes
CN103842365A (zh) * 2011-10-05 2014-06-04 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的环己基-4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]薁
WO2017191117A1 (fr) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Antagonistes du récepteur v1a destinés à une utilisation dans le traitement de maladies rénales
US11040977B2 (en) * 2013-12-05 2021-06-22 Hoffmann-La Roche Inc. Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crytalline forms thereof
US12083127B2 (en) 2017-12-08 2024-09-10 Hoffmann-La Roche Inc. Pharmaceutical formulation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108329051B (zh) * 2017-07-04 2020-09-18 中国科学院金属研究所 一种超高孔隙率和低坯体收缩率Y2SiO5多孔陶瓷的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074291A1 (fr) * 2003-02-19 2004-09-02 Pfizer Limited Composes de triazole utilises en therapie
WO2005068466A1 (fr) * 2004-01-13 2005-07-28 Pfizer Limited Composes utiles en therapie
WO2006021882A1 (fr) * 2004-08-25 2006-03-02 Pfizer Limited Triazolobenzodiazepines et leur utilisation en tant qu'antagonistes de la vasopressine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
PL205704B1 (pl) 1999-01-19 2010-05-31 Ortho Mcneil Pharm Inc Związki tricyklicznej benzodiazepiny, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
MXPA06003150A (es) 2003-09-17 2006-08-31 Johnson & Johnson Compuestos heterociclicos fusionados.
JP4085178B2 (ja) * 2004-05-17 2008-05-14 アステラス製薬株式会社 縮合ベンズアゼピン誘導体の新規製造法
CN1950374A (zh) 2004-05-25 2007-04-18 辉瑞产品公司 四氮杂苯并[e]甘菊环衍生物及其类似物
KR100840852B1 (ko) 2004-05-25 2008-06-23 화이자 프로덕츠 인크. 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체
EP1632494A1 (fr) 2004-08-24 2006-03-08 Ferring B.V. Antagonistes de la v1a vasopressine
CN101137381B (zh) 2005-03-15 2011-07-27 弗·哈夫曼-拉罗切有限公司 2-苯胺基-3,4-二氢-喹唑啉作为5ht5a受体拮抗剂的制药用途
US20080188478A1 (en) 2005-04-26 2008-08-07 Pfizer Inc. Compounds Useful In Therapy
WO2006123242A1 (fr) 2005-05-18 2006-11-23 Pfizer Limited Derives de 1, 2, 4-triazole en tant qu'antagonistes de la vasopressine
ATE536356T1 (de) 2007-01-12 2011-12-15 Hoffmann La Roche Spiropiperidin-glycinamid-derivate
WO2010057795A1 (fr) 2008-11-18 2010-05-27 F. Hoffmann-La Roche Ag Alkylcyclohexyléthers de dihydrotétrazabenzoazulènes
US8420633B2 (en) 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074291A1 (fr) * 2003-02-19 2004-09-02 Pfizer Limited Composes de triazole utilises en therapie
WO2005068466A1 (fr) * 2004-01-13 2005-07-28 Pfizer Limited Composes utiles en therapie
WO2006021882A1 (fr) * 2004-08-25 2006-03-02 Pfizer Limited Triazolobenzodiazepines et leur utilisation en tant qu'antagonistes de la vasopressine

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664216B2 (en) 2008-11-13 2014-03-04 Hoffmann-La Roche Inc. Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes
US8642590B2 (en) 2008-11-18 2014-02-04 Hoffmann-La Roche Inc. Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
US8227458B2 (en) 2008-11-28 2012-07-24 Hoffmann-La Roche Inc. Arylcyclohexylethers of dihydrotetraazabenzoazulenes
US8461152B2 (en) 2008-11-28 2013-06-11 Hoffmann-La Roche Inc. Arylcyclohexylethers of dihydrotetraazabenzoazulenes
WO2011120877A1 (fr) * 2010-03-31 2011-10-06 F. Hoffmann-La Roche Ag Aryl-cyclohexyl-tétraazabenzo[e]azulènes
US8420633B2 (en) 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
CN102834396B (zh) * 2010-04-13 2016-06-01 霍夫曼-拉罗奇有限公司 作为血管升压素拮抗剂的芳基-/杂芳基-环己烯基-四氮杂苯并[e]薁
CN102834396A (zh) * 2010-04-13 2012-12-19 霍夫曼-拉罗奇有限公司 作为血管升压素拮抗剂的芳基-/杂芳基-环己烯基-四氮杂苯并[e]薁
WO2011128265A1 (fr) * 2010-04-13 2011-10-20 F. Hoffmann-La Roche Ag Aryl-/hétéroaryl-cyclohexényl-tétraazabenzo[e]azulènes en tant qu'antagonistes de vasopressine
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
JP2014527993A (ja) * 2011-09-26 2014-10-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｖ１ａアンタゴニストとしてのオキシ−シクロヘキシル−４Ｈ，６Ｈ−５−オキサ−２，３，１０ｂ−トリアザ−ベンゾ［ｅ］アズレン類
AU2012314593B2 (en) * 2011-09-26 2016-09-29 F. Hoffmann-La Roche Ag Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists
KR20140079790A (ko) * 2011-09-26 2014-06-27 에프. 호프만-라 로슈 아게 V1a 길항제로서 옥시-사이클로헥실-4H,6H-5-옥사-2,3,10b-트라이아자-벤조[e]아줄렌
US8828989B2 (en) 2011-09-26 2014-09-09 Hoffmann-La Roche Inc. Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists
WO2013045373A1 (fr) * 2011-09-26 2013-04-04 F. Hoffmann-La Roche Ag Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulènes en tant qu'antagonistes de v1a
CN103827121A (zh) * 2011-09-26 2014-05-28 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的氧基-环己基-4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]薁
CN103827121B (zh) * 2011-09-26 2016-08-03 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的氧基-环己基-4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]薁
KR101682777B1 (ko) * 2011-09-26 2016-12-05 에프. 호프만-라 로슈 아게 V1a 길항제로서 옥시-사이클로헥실-4H,6H-5-옥사-2,3,10b-트라이아자-벤조[e]아줄렌
EA024990B1 (ru) * 2011-09-26 2016-11-30 Ф.Хоффманн-Ля Рош Аг ОКСИЦИКЛОГЕКСИЛ-4Н,6Н-5-ОКСА-2,3,10b-ТРИАЗА-БЕНЗО[e]АЗУЛЕНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ V1a
CN103842365A (zh) * 2011-10-05 2014-06-04 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的环己基-4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]薁
CN103842365B (zh) * 2011-10-05 2017-06-23 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的环己基‑4H，6H‑5‑氧杂‑2，3，10b‑三氮杂‑苯并[e]薁
US11040977B2 (en) * 2013-12-05 2021-06-22 Hoffmann-La Roche Inc. Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crytalline forms thereof
WO2017191117A1 (fr) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Antagonistes du récepteur v1a destinés à une utilisation dans le traitement de maladies rénales
US12083127B2 (en) 2017-12-08 2024-09-10 Hoffmann-La Roche Inc. Pharmaceutical formulation

Also Published As

Publication number Publication date
TWI389911B (zh) 2013-03-21
CN102216304B (zh) 2014-07-09
PE20110590A1 (es) 2011-08-31
US8642590B2 (en) 2014-02-04
KR20110074594A (ko) 2011-06-30
HRP20120816T1 (hr) 2012-11-30
PT2358714E (pt) 2012-10-09
CA2739900C (fr) 2016-11-08
BRPI0921058A2 (pt) 2018-10-16
CA2739900A1 (fr) 2010-05-27
CL2011001129A1 (es) 2011-10-07
EP2358714B1 (fr) 2012-08-01
ZA201102604B (en) 2012-09-26
CY1113692T1 (el) 2016-06-22
AR074354A1 (es) 2011-01-12
DK2358714T3 (da) 2012-08-20
EP2358714A1 (fr) 2011-08-24
RU2510397C2 (ru) 2014-03-27
TW201031666A (en) 2010-09-01
RU2011121438A (ru) 2012-12-27
IL212119A0 (en) 2011-06-30
SG171742A1 (en) 2011-07-28
IL212119A (en) 2014-12-31
SI2358714T1 (sl) 2012-11-30
MX2011005119A (es) 2011-05-30
JP5384659B2 (ja) 2014-01-08
KR101385433B1 (ko) 2014-04-14
JP2012508269A (ja) 2012-04-05
AU2009317386B2 (en) 2013-07-25
US20100125066A1 (en) 2010-05-20
AU2009317386A1 (en) 2010-05-27
CN102216304A (zh) 2011-10-12
PL2358714T3 (pl) 2012-12-31
ES2391374T3 (es) 2012-11-23

Similar Documents

Publication Publication Date Title
EP2358714B1 (fr) Alkylcyclohexyléthers de dihydrotétrazabenzoazulènes
EP2552919B1 (fr) Aryl-cyclohexyl-tétraazabenzo[e]azulènes
US8664216B2 (en) Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes
US8461151B2 (en) Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
WO2010060836A1 (fr) Arylcyclohexyléthers de dihydrotétrazabenzoazulènes pour emploi en tant qu'antagonistes du récepteur v1a de la vasopressine
JP5579925B2 (ja) ヘテロビアリール−シクロヘキシル−テトラアザベンゾ［ｅ］アズレン
AU2012314593B2 (en) Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980146033.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09747861

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009747861

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 212119

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2739900

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009317386

Country of ref document: AU

Date of ref document: 20091109

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 000978-2011

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 3264/CHENP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011535980

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/005119

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011001129

Country of ref document: CL

ENP Entry into the national phase

Ref document number: 20117011201

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12011500957

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2011121438

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0921058

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110517

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载